Evoq Remedies Ltd

Evoq Remedies has shown significant financial fluctuations, with net sales increasing to 11.76 Cr in March 2025 from 4.05 Cr in March 2024, but down from 20.39 Cr in March 2023. The company reported a cash flow outflow of -14.00 Cr in March 2025, indicating a volatile financial trajectory.

Evoq Remedies has experienced fluctuating financial performance, with net sales rising to 11.76 Cr in Mar'25 but down from a peak of 20.39 Cr in Mar'23. The company reported an operating loss of -2.23 Cr in Mar'25, a decline in profitability, and negative cash flow of -14.00 Cr, indicating financial challenges.

Evoq Remedies will announce its results on 09 October 2025.

As of 01-October, Evoq Remedies Ltd's stock price is declining at 3.90, down 1.27%, with a significant 50% drop year-to-date and a 75.62% decline over three years. Despite a recent increase in delivery volume, the stock continues to underperform against the market and its sector, indicating a bearish trend.

As of 29-Sep, Evoq Remedies Ltd's stock price is at 4.15, down 4.82%, and has underperformed its sector. Despite a one-month increase of 35.18%, it has fallen 46.79% year-to-date, with declining investor participation contributing to its recent price drop.

As of 24-Sep, Evoq Remedies Ltd is experiencing a price increase to 4.55, up 9.11%, with strong short-term returns of +27.09% over one week and +32.65% over one month, despite a year-to-date decline of -41.67%. The stock is outperforming its sector but shows decreased investor participation, indicating mixed signals regarding its long-term trend.

As of 23-Sep, Evoq Remedies Ltd's stock price is at 4.17, down 2.34% after a trend reversal. Despite a strong short-term performance, it has significantly underperformed the sector and the broader market year-to-date.

As of 22-Sep, Evoq Remedies Ltd's stock price is at 4.27, up 9.77% over the last two days, with a total return of 19.27% during this period. Despite a year-to-date decline of 45.26%, the stock has significantly outperformed its sector and the broader market recently, indicating improving investor sentiment.

As of 19-Sep, Evoq Remedies Ltd's stock price is at 3.93, up 9.78% today, but it has a year-to-date decline of 49.62%, indicating significant volatility and challenges in maintaining investor confidence despite recent gains.

As of 18-Sep, Evoq Remedies Ltd is priced at 3.58 with no change, underperforming its sector by 1.05% and trading below all key moving averages. The stock has declined 2.72% over the past week and has significant losses of -10.05% and -59.59% over the past month and year, respectively, indicating a lack of investor interest and confidence compared to the Sensex, which has gained 1.80% in the same period.

As of 17-Sep, Evoq Remedies Ltd's stock price is at 3.58, having increased by 3.17% after two days of decline, but it remains below key moving averages, indicating a bearish trend. The stock has significantly underperformed year-to-date and over the past year, contrasting with the broader market's positive performance.

As of 15-Sep, Evoq Remedies Ltd is priced at 3.62, down 1.9%, and has significantly underperformed its sector and the broader market, with a year-to-date decline of 53.59%. The stock is trading below all major moving averages and has seen a drastic drop in investor participation.

As of 12-Sep, Evoq Remedies Ltd's stock price is at 3.69, showing a slight increase but remains down 52.69% year-to-date and 82.40% over three years, indicating significant long-term struggles compared to the broader market. The stock's recent slight gain follows three days of decline, but overall performance is weak, with decreased investor participation.

As of 11-Sep, Evoq Remedies Ltd's stock price is declining at 3.68, down 2.39%, with significant underperformance indicated by a year-to-date decline of 52.82% compared to the Sensex's gain of 4.36%. Despite a slight weekly gain, the stock remains below key moving averages, reflecting a challenging market environment.

As of 10-Sep, Evoq Remedies Ltd is priced at 3.77, down 2.33% and has declined 5.75% over the last two days. Despite a slight increase in investor participation, the stock has underperformed significantly year-to-date, with a 51.67% drop compared to the benchmark Sensex's gain of 4.21%.

As of 09-Sep, Evoq Remedies Ltd's stock price is at 3.86, down 3.5%, and has underperformed its sector by 4.13%. Despite a recent short-term gain of 4.04%, the stock has significantly declined by over 50% year-to-date, indicating a negative long-term trend compared to the broader market.

As of 08-Sep, Evoq Remedies Ltd's stock price is at 4.00, up 3.36% recently, but it has declined 48.72% year-to-date. The stock has shown volatility, outperforming the Sensex in the short term while struggling over longer periods.

As of 05-Sep, Evoq Remedies Ltd is experiencing a price increase to 3.87, reflecting a 5.74% upward change. Despite a recent gain of 26.06% over the past week, the stock has a significant year-to-date decline of 50.38%, indicating ongoing volatility and uncertainty.

As of 04-Sep, Evoq Remedies Ltd is priced at 3.66, down 0.27%, with a recent downward trend and mixed short-term performance. Despite a weekly gain of 18.06%, it has underperformed significantly year-to-date, declining 53.08% compared to the Sensex's 3.30% gain.